Skip to content

Clinical trials

Myeloproliferative Disorders trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myeloproliferative Disorders Country / region: Italy Clear all

67 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20022
20032
20053
20073
20081
20092
20111
20121
20135
20144
20151
20173
20183
20194
20204
202110
20227
20233
20241
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed28
Active, not recruiting13
Recruiting12
Terminated9
Unknown status4
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Incyte Corporation11
Novartis Pharmaceuticals7
Fred Hutchinson Cancer Center5
Azienda Ospedaliero-Universitaria di Parma4
European Organisation for Research and Treatment of Cancer - EORTC4
Celgene3
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS3
AbbVie2
Fondazione IRCCS Policlinico San Matteo di Pavia2
Icahn School of Medicine at Mount Sinai2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myeloproliferative Disorders67
Primary Myelofibrosis31
Thrombocythemia, Essential18
Polycythemia Vera17
Leukemia, Myeloid, Acute16
Multiple Myeloma14
Precursor Cell Lymphoblastic Leukemia-Lymphoma12
Hematologic Diseases11
Leukemia, Myelomonocytic, Chronic10
Hodgkin Disease9

Trials

Showing 26 to 50 of 67. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.